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Abstract
Although monkeypox virus (MPXV) studies in wild rodents and non-human primates have generated important knowledge
regarding MPXV pathogenesis and inferences about disease transmission, it might be easier to dissect the importance of
virulence factors and correlates of protection to MPXV in an inbred mouse model. Herein, we compared the two clades of
MPXV via two routes of infection in the BALB/c and C57BL/6 inbred mice strains. Our studies show that similar to previous
animal studies, the Congo Basin strain of MPXV was more virulent than West African MPXV in both mouse strains as
evidenced by clinical signs. Although animals did not develop lesions as seen in human MPX infections, localized signs were
apparent with the foot pad route of inoculation, primarily in the form of edema at the site of inoculation; while the Congo
Basin intranasal route of infection led to generalized symptoms, primarily weight loss. We have determined that future
studies with MPXV and laboratory mice would be very beneficial in understanding the pathogenesis of MPXV, in particular if
used in in vivo imaging studies. Although this mouse model may not suffice as a model of human MPX disease, with an
appropriate inbred mouse model, we can unravel many unknown aspects of MPX pathogenesis, including virulence factors,
disease progression in rodent hosts, and viral shedding from infected animals. In addition, such a model can be utilized to
test antivirals and the next generation of orthopoxvirus vaccines for their ability to alter the course of disease.
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Introduction
Human monkeypox (MPX) is a sporadic smallpox-like zoonotic
viral exanthemata disease that occurs in the rain forests of Central
and West Africa. The virus was discovered in 1958 from primate
tissues[1]. The disease has similar manifestations to those of
smallpox but tends to be less severe. The virus MPX belongs to the
Orthopoxvirus genus of Poxviridae, and shares many biochemical and
physical properties with other orthopoxviruses, such as vaccinia
and variola (causative agent of smallpox). MPXV is endemic in the
rain forests of Central and West Africa, causing sporadic outbreaks
in remote villages, where it is believed to result from close contact
between humans and animals living in the rain forests[2–4].
MPXV infection is thought to be acquired most commonly by
direct percutaneous contact, mucosal or respiratory exposure to
tissues or fluids of infected animals[5].
An outbreak of MPXV recently occurred in the US in 2003[6–
9]. Imported African rodents were implicated as the source of the
outbreak. Studies have demonstrated the existence of two
genetically distinct variants of the virus: West African and Congo
Basin clades[10,11]. The strain that caused the US outbreak
belonged to the West African clade, which clinical and
epidemiological data has shown is associated with less severe
disease[10].
Several animal models have been used to study MPXV
pathogenesis including rabbits and newborn white mice[12],
cynomolgus monkeys[13], squirrels[14–16], prairie dogs[16,17]
and dormice[18]. While studies in wild rodents and non-human
primates have generated important knowledge regarding MPXV
pathogenesis and inferences about disease transmission, it might be
easier to dissect the importance of virulence factors and correlates of
protection to MPXV in an inbred mouse model. Laboratory mouse
models are very versatile, allowing the roles of individual
components of innate and adaptive immunity to be investigated
through well-characterized inbred strains as well as gene deficient
mice. With an inbred mouse model, we can investigate many
unknown aspects of MPXV pathogenesis, including: virulence
factors, disease progression in rodent hosts, and viral shedding from
infected animals; an index of the transmission potential to humans
and other animals. In addition, such a model can be utilized to test
anti-virals and the next generation of orthopoxvirus vaccines for
their ability to alter the course of disease.
Materials and Methods
Ethics Statement
All animals were handled in strict accordance with good animal
practice as defined by the relevant national and/or local animal
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Institutional Animal Care and Use Committee (IACUC) under an
approved protocol (1457REGMOUC).
Animal Maintenance
Inbred C57BL/6 and BALB/c mice (6–7 weeks-old) were
obtained from Harlan Sprague Dawley (Indianapolis, IN). During
experimental infections animals were housed individually in mouse
cages with aerosol filter tops and kept in a Duo-Flow biosafety
cabinet (Lab Products, Inc.) in the Biosafety Level 3 (BSL-3)
animal facility at the CDC. All animal studies were conducted in
the Biosafety Level 3 (BSL-3) animal facility at the CDC and
approved by the CDC Institutional Animal Care and Use
Committee (IACUC) under an approved protocol (1457RE-
GMOUC).
Viruses
The West African strain of MPXV used in these studies had
been isolated during the 2003 U.S. outbreak and is designated as
MPXV-2003-044 and has previously been fully sequenced and
identified as a West African MPXV strain[11]. This isolate is from
a prairie dog associated with the index case in Wisconsin during
the U.S. outbreak[11,19]. The MPXV collected from the Congo
Basin was isolated during a 2003 outbreak in the Republic of
Congo (ROC) and is designated as MPXV-2003-358. The later
isolate was from a 10-year-old girl infected in Impfondo, ROC,
and has also been fully sequenced and thus characterized as a
Congo Basin clade representative MPXV[11]. Both viruses had
undergone two passages in African green monkey kidney cells
(BSC-40) prior to seed pool production; purified preparations of
virus were used for animal challenges.
Inoculation of Animals
Groups of five BALB/c and C57BL/6 mice were inoculated via
subcutaneous injection in the footpad (FP) or via an intranasal (IN)
route with either the West African or Congo Basin MPXV strain
(10
5 p.f.u. in a total volume of 10 ml per mouse, similar to an
inoculum the author’s have used in a previous study). In addition,
two mice of each mouse strain were mock infected with PBS via
the FP or IN route. Decontamination of all equipment, surfaces,
gloves, etc. with 20% Lysol H followed by 10% ethanol was done
between strains to alleviate the chance of cross-contamination.
Isoflurane-soaked cotton balls placed in 50 ml conical tubes were
used to anesthetize mice. The appropriate virus was then
administered with an eppendorf pipette into the nostrils (5 ml into
each nostril) for the IN route. For the FP route, the appropriate
virus (10 ml) was administered into the right footpad by
subcutaneous injection using a 28-gauge needle. Care was taken
to avoid the intramuscular and/or intradermal tissue.
Sampling, Necropsy and Tissue Specimen Collection
Overall activity and clinical observations were made on a daily
basis. Animals were weighed individually every week, or more
often if needed. Based on what the author’s have seen in previous
studies with prairie dogs[17], animals were sampled for 30 days
after infection to allow full recoveries from viral infection. At day
30 post infection (p.i.), animals were humanely euthanized and
blood, urine, feces and swabs from oral, nasal, and rectal orifices
were collected from all animals. Swabs were collected with sterile
individual Dacron swabs and stored frozen without diluents.
Serum was separated from whole blood collected by either nobuto
strips (Advantec MFS, Inc.) or direct cardiac sticks after
euthanasia. Mice were humanely euthanized and quickly frozen
at 270uC. The bodies were subsequently thawed and necropsies
were performed utilizing full BSL-3 personal protective equip-
ment. Samples collected at necropsy included brain, heart, lung,
spleen, liver, kidney, tongue, lymph nodes, gonad, and skin.
Between sample collections, all instruments (scalpel, scissors,
forceps, etc.) were cleaned and decontaminated using 3% Amphyll
and 10% Clorox bleach solutions and then rinsed in sterile water.
Tissues and swabs were frozen at 270uC prior to further
processing for both DNA analysis and virus isolation (see below).
Sample Preparation
All sample processing was performed under BSL-3 conditions.
For swabs, 400 ml of PBS was added. The Swab extraction tube
systems (SETS) (Roche) protocol was used to recover swab
samples. 100 ml from swabs or blood samples were used to extract
genomic DNA using the AquaPure DNA isolation kit (Bio-Rad).
The remaining swab lysate was used for virus isolation (see below).
Tissue and fecal samples placed in disposable dounce homoge-
nizers with 1.0 ml of PBS and the tissue was homogenized
thoroughly. About 100 ml of the homogenized sample was used to
extract genomic DNA (AquaPure DNA isolation kit) and the
remaining volume was used for virus isolation (see below).
Real-Time PCR Analysis
Samples were tested by real-time PCR using forward and
reverse primers and probe which are complimentary to regions of
the well conserved E9L (DNA polymerase) gene of orthopox-
viruses[20]. Serial 10-fold dilutions of MPXV DNA (10 fg–1 ng)
were used as a positive controls. Reactions were placed in an ABI
7900 or 7900HT real time PCR detector (Applied Biosystems) and
subjected to the following thermal cycle parameters: 95uC for 10
minutes, then 95uC for 15 seconds and 63uC for 1 minute for 45
cycles. A sample was considered positive if the cycle threshold (Ct)
value for both duplicates was 37 or below. A weak positive was a
sample with Ct values of 38–39. PCR samples were called
inconclusive if only one of the duplicate samples tested positive or
weakly positive.
Virus-Tissue Infectivity
To screen tissues for the presence of MPX virus, previous
analysis has demonstrated that real-time PCR detection of MPXV
DNA was significantly more sensitive than the detection of viable
virus (plaque forming units)[6]. For the current study, specimens
were first tested for the presence of orthopoxvirus (OPXV) DNA
by PCR and, if positive, they were subsequently evaluated for
viable virus by tissue culture inoculation. Each swab, feces or
individual tissue sample to be assayed was titrated using 10-fold
dilutions of swab sample or tissue homogenate in a standard
OPXV plaque assay on BSC-40 cell monolayers, incubated at
36uC, 6% CO2 for 72 hours, and subsequently stained with 2X
crystal violet stain and formalin to reveal plaques.
Serologic Analysis
As previously described[17], a modified ELISA was used for
analysis of anti-Orthopoxvirus immunoglobulin types A and G.
Because of the small amount of blood collected from each animal,
mouse sera were pooled for each group. Pooled sera samples were
added to both halves of the plates at a dilution of 1:100 in assay
diluent. Optical densities (ODs) were read on a spectrophotometer
at 450 nm. Values reported represented the average of duplicate
wells for each sample. Both positive and negative human anti-
vaccinia sera were used as assay controls. The BSC-40 cell lysate
half of each plate was used to generate a cut-off value (COV) for
Monkeypox Challenge in Mice
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adding two standard deviations. Specimens were considered
positive if the test sample’s value was above the COV.
Statistical Analyses
Nonparametric statistical tests were used in the analysis as data
were not normally distributed[21]. Comparisons of weight loss
between strains, routes of infection, and mouse type were made
using the Wilcoxon rank-sum test. In order to evaluate weight
differences, day zero weights were used as the baseline and the
lowest weight measured thereafter was used to calculate percent
weight loss in each animal. A p-value of ,0.05 was considered
significant.
Results
Congo Basin FP
Until day 6 p.i., no overt signs of disease were noted for any
animal. Beginning on day 6 all mice inoculated in the FP with the
Congo Basin MPXV had noticeable edema at the site of
inoculation, compared to control FP mice, which showed no signs
of edema at any time throughout the study. BALB/c mice had
greater edema compared to C57BL/6 mice (Table 1). By day 7
p.i., one of the five C57BL/6 mice and two of the five BALB/c
mice had a FP severely swollen and affected animals were not
putting any pressure on the appendage. One of these BALB/c
mice also had a ruffled hair coat, and the right leg and lymph node
appeared to be swollen. On day 9, all C57BL/6 mice still had a
slightly swollen FP, but none of these animals were favoring the
foot. In contrast, BALB/c FP animals were still significantly
swollen, with one mouse limping. By day 13 p.i., edema had
resolved in all the FPs and all mice were walking normally. None
of the C57BL/6 FP inoculated mice lost weight throughout the
course of the study (figure 1). Of the BALB/c mice, 1 of 5 lost
7.3% of its starting body weight between day 0 and day 9. All of
the mice inoculated in the FP with Congo Basin MPXV survived
infection and were euthanized on day 30 p.i., at which time
representative samples were taken for testing. Two BALB/c mice
and one C57BL/6 mouse had positive or inconclusive PCR
samples (Table 1). All PCR positive and inconclusive samples were
titrated, however none yielded viable virus (Table 1).
Congo Basin IN
As was seen with the Congo Basin FP model, no observable
symptoms were noted for the first 6 days p.i. Four of five BALB/c
mice inoculated IN with the Congo Basin MPXV showed a ruffled
coat on days 6–9 compared to none of IN infected C57BL/6 mice.
However, weight loss was observed in both strains of mice
(Figure 1). Four of the five C57BL/6 mice had weight loss between
days 0–9 ranging between 7.3–14% starting body weight
(Mean=8.16%). Similarly, 3 of the 5 BALB/c mice also had
weight loss between days 0–9, ranging between 3–19% starting
body weight (Mean=9.14%). Otherwise, no obvert signs of
morbidity (i.e., lesions) were observed in the IN Congo Basin
inoculated mice. As was seen with the Congo FP group, all of the
mice survived infection and were euthanized on day 30 p.i., at
which time representative samples were taken for testing. Two
C57BL/6 mice had inconclusive PCR spleen samples, both of
which were negative for viable virus. None of the BALB/c mice
had MPXV PCR positive or inconclusive samples.
West African FP
Similar to the Congo Basin animals, until day 6 p.i., no overt signs
of disease were noted for any mice in this group. Only one out of five
BALB/c mice was slightly favoring the inoculated foot and had a
ruffled coat on day 6. However, beginning on day 7 p.i., all mice
Table 1. Comparison of descriptive disease presentation and molecular findings in mice infected with monkeypox virus (MPXV).
West African MPXV Congo Basin MPXV
C57BL/6 BALB/c C57BL/6 BALB/c
Foot pad edema 5/5 FP
"
0/5 IN
5/5 FP
"
0/5 IN
5/5 FP
{
0/5 IN
5/5 FP
{
0/5 IN
Limping 5/5 FP
0/5 IN
2/5 FP
0/5 IN
5/5 FP*
0/5 IN
5/5 FP*
0/5 IN
Weight loss 0/5 FP
0/5 IN
0/5 FP
0/5 IN
0/5 FP
4/5 IN
1/5 FP
3/5 IN
Ruffled hair coat 0/5 FP
0/5 IN
1/5 FP
0/5 IN
0/5 FP
0/5 IN
1/5 FP
4/5 IN
Positive PCR animals 1/5 FP
1/5 IN{
1/5 inc FP
3/5 IN
1/5 inc FP
2/5 inc IN
2/5 FP{
0/5 IN
Positive and inconclusive
PCR samples
FP: Li
IN: LN, Sk,
RS-inc
FP: Lu-inc
IN: (1) Lu
(2) BL, Ki-inc
(3) LN
FP: Sp-inc
IN: Sp-X 2 inc
FP: (1) Li, Lu, Ki
(2) Lu-inc
OPXV antibodies FP: pos
IN: pos
FP: pos
IN: pos
FP: pos
IN: pos
FP: pos
IN: weak pos
C57BL/6 and BALB/c mice were challenged with either Congo Basin MPXV or West African MPXV by an intranasal (IN) or foot pad (FP) route of infection (n=5 ine a c h
group). Samples for PCR and serology were taken at 30 days post infection.
"Mild swelling noted.
{Severe swelling noted.
*Severe limping with some animals putting little/no weight on limb.
{More than 1 sample positive or inconclusive.
Inc: Inconclusive PCR sample.
Positive/Inconclusive PCR samples: Li (liver), LN (lymph node), Sk (skin), RS (rectal swab), Lu (lung), BL (blood), Ki (kidney), Sp (spleen).
doi:10.1371/journal.pone.0008912.t001
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the site of inoculation. The edema that was observed in the West
African FP inoculated mice was comparatively less than that observed
in the Congo Basin FP animals. Additionally, by day 9 for the
C57BL/6 mice, and day 11 for the BALB/c mice, the edema had
resolved completely. This was slightly earlier than that seen with the
Congo Basin MPXV FP animals. None of the West African FP
inoculated mice lost weight throughout the course of the study or
developed any lesions. As was seen for both Congo Basin inoculation
routes, all animals in this group survived infection and were
euthanized 30 days p.i. with representative samples collected for
testing. One BALB/c mouse had the lung sample test inconclusive
and one C57BL/6 mouse had a positive lung sample for MPXV
DNA. However, neither of these samples was positive for viable virus.
Western African IN
Unlike the Congo Basin IN challenged animals, none of the
mice in the West African MPXV IN inoculated group developed
any obvious signs of morbidity. All animals survived infection and
were euthanized 30 days p.i., with representative samples collected
for testing. Although no clinical symptoms were observed, some
samples yielded PCR positive results (Table 1), however none
yielded viable virus.
Control Mice
None of the four control, mock-infected mice showed any signs
of illness (i.e., edema, weight loss, lesions). Furthermore, all
necropsy samples from these control mice tested negative for
MPXV DNA and all four animals were negative for OPXV
antibodies (Figure 2).
Serology
Pooled samples from the groups of mice collected at time of
necropsy were used for serology. At a 1:100 dilution, all groups
were considered positive for OPXV antibodies on the day of
necropsy, day 30 p.i. (Figure 2). Because of the small amounts of
serum used and the different collection methods, we can not
compare the serology results between groups, except to confirm
that all seroconverted.
Discussion
In the present study, we compared the infection produced by
West African and Congo Basin MPXV clades in inbred BALB/c
and C57BL/6 mice. Subtle differences in pathogenicity between
the two strains of MPXV were observed in this study. As seen in
previous animal studies[10,17], the Congo Basin strain of MPXV
was more virulent than the West African strain as evidenced by the
symptoms we observed. We have determined that laboratory mice
may be a suitable animal model to study MPXV pathogenesis and
future studies to further characterize the mouse innate and
adaptive immune responses to monkeypox infection will help in
understanding the host-virus interactions that lead to more
attenuated disease presentations compared to people and other
animals such as prairie dogs.
Figure 1. Mean percent weight change comparison of mice infected with MPXV. BALB/c and C57BL/6 mice were challenged with either
Congo Basin MPXV (A, B) or West African MPXV (C, D) by either an intranasal (n=5) or foot pad (n=5) route of infection.
doi:10.1371/journal.pone.0008912.g001
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model, whereas generalized signs and symptoms were more
evident in the IN challenge models. On the whole, for both mouse
strains and both inoculation routes, the West African MPXV
disease was less severe than that observed in the Congo Basin
challenged groups. Although FP edema was observed in all mice
that were FP inoculated, the edema observed in the West African
infected group was comparatively less (no/slight limp) than that
observed in the Congo Basin FP mice (severe limp with animal
putting little/no weight on inoculated leg). Furthermore, the
edema resolved in a shorter time period in the West African
MPXV infected mice compared to the Congo Basin MPXV
infected mice. Additionally, one of the Congo Basin FP animals
lost weight, whereas none of the West African FP animals lost
weight. When we compare the IN route of infection, unlike the
Congo Basin IN animals which displayed some ruffled coats and
weight loss, the animals in the West African IN group did not
develop any noticeable symptoms. Both mouse strains that were
challenged IN with Congo Basin MPXV had an observed trend of
increased weight loss compared to West African MPXV
challenged mice. However the weight loss was not considered
statistically significant (C57BL/6 mice: mean % weight
loss=0.56% West African vs. 8.16% Congo Basin, p=0.076;
BALB/c mice: mean % weight loss=1.08% West African vs.
9.14% Congo Basin, p=0.099). However, utilizing the blood
collection methods in this study, the immune response observed in
the Congo Basin IN challenged mice was less than that observed in
the West African IN challenged mice. Future studies on tracking
virus during the course of infection may help to clarify this
apparent difference in viral clearance by or virus presentation to
the immune system.
The edema that occurred in the FP groups with both strains of
MPXV suggests an acute inflammation. The observation that only
mild ruffled coats and weight loss was seen in the Congo Basin IN
animals and no observable symptoms in the West African IN
animals could imply more of a generalized inflammatory response
to infection in the Congo Basin IN infected animals. Alternatively,
the weight loss that was seen in the Congo Basin IN animals may
have been caused by localized inflammation in the nasal and oral
cavities of these Congo Basin IN challenged animals resulting in
decreased food consumption. However, the findings that all
MPXV challenged groups had seroconverted at time of necropsy
suggests that the animals did develop infection. Not surprisingly
and as previously seen in the authors’ studies with prairie dogs[17],
no viable virus was found in necropsy samples at 30 days p.i.
However, additional evidence of systemic infection is provided by
the positive PCR results in several tissue types including lungs,
blood, lymph node, skin, liver and kidney samples at 30 days p.i.
Although PCR positive tissue samplings were not found at day 30
in the Congo Basin IN challenged animals, in the West African
MPXV IN challenged animals in which no symptoms were
observed, at 30 days p.i. animals had several positive PCR samples
suggestive of systemic infection.
Although all mice in the present study were considered OPXV
antibody positive, it is noteworthy that the antibody levels seen in
these animals were less than what we have observed when
challenging prairie dogs with a comparable inoculums of
MPXV[17]. Although these ELISA plates were run on different
days, because our negative and positive controls are similar
throughout ELISA runs it is possible to compare the data. The low
levels of antibodies detected in the mouse sera could reflect the
degree of infectious virus that is presented to the immune system in
these inbred mouse strains. Future studies may better address the
mouse innate and adaptive immune responses to monkeypox
infection, and will help in understanding the host-virus interactions
that lead to more attenuated disease presentations.
Inbred mice are as genetically alike as possible, being
homozygous at virtually all of their loci. Such genetic homogenous
models are ideal for studying human pathogens as symptoms of
disease are very similar or identical between animals. Results
therefore are often more easily interpreted than in a wild or out
bred animal model in which genetic diversity can sometimes lead
to conflicting or confusing results. Inbred mice, including BALB/c
and C57BL/6 strains, are a very controlled and well understood
Figure 2. Serologic analysis of mice infected with MPXV. BALB/c and C57BL/6 mice were challenged with either Congo Basin MPXV (CB) or
West African MPXV (WA) by either an intranasal (IN) or foot pad (FP) route of infection (n=5 in each group). Additionally, 4 mice were mock infected
with PBS (controls). Because of the small amount of blood collected, mouse sera were pooled from each group of animals for testing. Data are shown
with the positive controls as well as without positive controls (inset) in order to better visualize samples with low levels of antibodies.
doi:10.1371/journal.pone.0008912.g002
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for these animals. It would also be possible to create knockout mice
to further understand and characterize the relationship between
the immune system and the virus. Having such an inbred mouse
model for the study of MPXV could greatly increase our wealth of
knowledge about this serious human pathogen.
A recent paper by co-authors of this manuscript [22] used in vivo
imaging to study IP (intraperitoneal) inoculation of monkeypox in
immunocompetent and immuno-compromised BALB/c mice.
Although the IP route of infection does not mimic the natural
transmission of this disease, the previous results were similar to our
study in that the innate immune system in the immunocompetent
animals kept the virus localized to the site of infection while the
immuno-compromised animals developed systemic infections.
Also, in both groups of animals in the previous study, the Congo
Basin strain of monkeypox was more virulent which is also
congruent with our results. Future in vivo imaging studies with an
IN route of infection would better mimic natural infection routes,
and would provide a better understanding of ‘‘natural’’ patterns
viral trafficking and the immune response(s) that protect against
MPX infection in immunocompetent animals.
We have demonstrated that these mouse strains would not likely
suffice as a model for human MPX disease due to the more subtle
disease presentation compared to the disease course seen in
humans, but may prove informative in the understanding of
immune response which makes certain animals more capable of
efficiently clearing MPXV. Both mice strains had similar clinical
presentations, with the exception of more BALB/c mice
developing ruffled coats when challenged with Congo Basin
MPXV. Therefore, the BALB/c mouse strain should probably be
used in future studies. However, based on symptoms of morbidity,
the Congo Basin MPXV clade was more virulent in both strains of
mice. The FP inoculation route provided the visual symptom of
edema with both MPXV strains. However, the animals challenged
IN with Congo Basin MPXV lost weight and 4/5 BALB/c mice
developed ruffled coats unlike West African IN challenged
animals, suggesting that the IN route might be better for clade
comparison. Additionally, as previously mentioned, the IN route is
the more probable natural route of infection, and therefore will be
used in future studies. In particular, this mouse model may be used
for non-invasive in vivo imaging in order to unravel many unknown
aspects of MPX pathogenesis, including virulence factors, disease
progression in rodent hosts, and viral shedding from infected
animals. Furthermore, an in vivo inbred mouse model could be
used to test antivirals and the next generation of OPXV vaccines
for their ability to alter the course of monkeypox disease.
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